Levosimendán Zentiva

Levosimendan, the active ingredient in Levosimendán Zentiva, is a calcium sensitizer presented as an intravenous solution for intravenous use. It is indicated for acute decompensated heart failure and cardiogenic shock in hospitalized patients, where it improves cardiac contractility and systemic perfusion.

GNH USA supplies Levosimendán Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Levosimendan is used in the management of severe cardiac conditions that require rapid improvement of contractility and vascular tone.

Acute decompensated heart failure: enhances cardiac output and relieves congestion. Cardiogenic shock: stabilises haemodynamics and supports organ perfusion.

Levosimendan may be associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypotension: reduction in blood pressure, especially after infusion start. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Flushing: transient warmth and reddening of skin. - Tachycardia: increased heart rate. - Arrhythmia: non‑sustained ventricular ectopy.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring intervention. - Ventricular arrhythmias: sustained tachyarrhythmias. - Myocardial ischaemia: chest pain or ECG changes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Liver enzyme elevation: increased transaminases. - Electrolyte disturbances: significant shifts in potassium or magnesium.

Levosimendan should be administered with careful clinical monitoring and awareness of specific safety considerations.

Monitor blood pressure: watch for hypotension during and after infusion. Assess renal function: adjust use in severe renal impairment. Evaluate electrolytes: correct potassium and magnesium abnormalities before administration. Use cautiously after recent myocardial infarction: risk of ischaemia may be increased. Avoid in severe baseline hypotension: may exacerbate low blood pressure. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other cardiovascular agents, requiring attention to dosage and patient status.

Major Interactions (Avoid): - Concurrent vasodilators (e.g., nitroglycerin): may cause profound hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations. - Other inotropes (e.g., dobutamine): risk of excessive cardiac stimulation.

Moderate Interactions (Monitor Closely): - Diuretics: may amplify electrolyte shifts. - ACE inhibitors or ARBs: additive blood‑pressure lowering effect. - Beta‑blockers: may blunt desired inotropic response. - Calcium‑channel blockers: potential for altered vascular tone. - Anti‑arrhythmic drugs: monitor rhythm changes.